Metacrine nabs $65 mln Series C

San Diego-based Metacrine, a developer of therapies for patients with liver, gastrointestinal and metabolic diseases, has raised $65 million in Series C financing. Venrock Healthcare Partners led the round with participation from other investors that included Franklin Templeton Investments, Deerfield Management, Arrowmark Partners, Invus, Lilly Asia Ventures, Vivo Capital, Arch Venture Partners, venBio, Polaris Partners, New Enterprise Associates and Alexandria Venture Investments.

Source: Press Release